Bachelor Thesis - DCF of biopharma firm (CELG) - No concrete research reports/sources for the forecast of the FCF available

Hello guys, I am a student from a European university. As part of my bachelor thesis I have to do a DCF analysis on a biopharma company (CELG). However, I have problems finding useful information to forecast the FCF; so far I only went through company filings and presentations.

I am looking for industry and equity research related to future cash flows. Through my uni I have access to Reuters EIKON and WRDS (Wharton Research). Unfortunately, I did not find any useful data regarding this there. I only found company snapchots on EBSCO by Acquis Data and MarketLine and one equity research report from CS from 2016 on Google.

My Questions: -Where do you find such data as a student? I am expected to write academically, which I find kind of hard as I have not a lot of information to base my assumptions on right now (and not academic sources).

-Into how much detail would you go for the FCF forecast (individual drug forecasts for the FCF, patent expirations, etc.)? I am still unsure on this as I have ~ 7 weeks for the thesis and still have to get an overview.

Would really appreciate it.

Thanks in advance.

1 Comments
 

Omnis aspernatur unde consequatur est tenetur quisquam repellat. Consequatur aut sit neque voluptas impedit tenetur. Qui adipisci molestias voluptas nostrum harum odit eum sit.

Neque facilis mollitia enim. Delectus rem maiores blanditiis. Ut quis nobis consequuntur blanditiis consequatur placeat consequatur et. Eligendi sequi iste aut nulla facere.

Et harum excepturi quidem aut. Quia corporis nostrum vel dolor sit eligendi. Excepturi velit accusantium provident dicta non sit facilis.

I'm an AI bot trained on the most helpful WSO content across 17+ years.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 02 98.8%
  • Evercore 01 98.3%
  • BMO Capital Markets 12 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.7%
  • JPMorgan No 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (15) $434
  • Associates (44) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (79) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
kanon's picture
kanon
99.0
4
Secyh62's picture
Secyh62
99.0
5
CompBanker's picture
CompBanker
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
DrApeman's picture
DrApeman
98.9
8
dosk17's picture
dosk17
98.9
9
GameTheory's picture
GameTheory
98.9
10
bolo up's picture
bolo up
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”